... Introduction: Pancreatic cancer remains a lethal disease with limited therapeutic options. Treatment with PARP inhibitors has been successfully described mainly in patients with germline mutation in BRCA1/2. The efficacy of PARP inhibitors in patients with alterations in other genes in the homologous repair...

... sequencing (NGS) is an established tool that enables multigene panel analysis. Methods: This NGS tissue-based analysis, conducted at a German pancreatic cancer center, included 128 patients between January 2016 and January 2021. Results: A targetable lesion was detected in 15.6% of patients. BRCA1/2...

... and resource allocation for colorectal and pancreatic cancer in the context of the pandemic. Based on a selective literature review as well as empirical and ethical analyses, the research team of the CancerCOVID Consortium drafted recommendations for prioritizing diagnostic and treatment measures for both...

... fields of medical oncology of the ESMO 2023 summarized by the AIO are presented elsewhere. The PREOPANC trial demonstrated a benefit for a neoadjuvant gemcitabine-based chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer (PDAC) [ 1, 2 ]. Referring...

...Jérôme Schwingel; Miriam Decker; Lisa Schneider; Carsten Johannes Stürmer; Manfred P. Lutz Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is increasingly common. Screening for pancreatic cancer is not well established but might increase the chance of detection...

... Pancreatic cancer Pancreatic ductal adenocarcinoma Real-world data FOLFIRINOX Gemcitabine/nab-paclitaxel Systemic treatment of locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) remains an area of great clinical need. During the past decade, the multi-drug regimens...

... potentially curative approach in the treatment of pancreatic cancer. To analyse the clinical impact of a structured post-operative follow-up programme, we retrospectively analysed a cohort of resected pancreatic adenocarcinoma patients treated at LMU Munich. Methods: Pancreatic adenocarcinoma patients who...

...; Giampaolo Tortora; Vincenzo Valentini Introduction: Pancreatic cancer (PC) represents an unfavorable prognosis condition, even in patients with resectable disease. The aim of this series was to investigate the role of treatment intensification with adjuvant chemoradiation (CRT) in radically resected PC...

..., instructions or products referred to in the content or advertisements. 2022 Pancreas Pancreatic cancer Pancreatic stellate cells Retinoic acid receptors NIH Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. It is the fourth leading cause of cancer-related...

...Alexander Queck; Sharra Elango; Christine Koch; Dirk Walter; Jennifer Schmidt; Jonel Trebicka; Jörg Trojan; Ursula Pession; Fabian Finkelmeier; Oliver Waidmann Background and Aims: While irresectable pancreatic cancer has still a dismal overall prognosis, evidence about the optimal chemotherapy...

...Janna-Lisa Velthaus; Peter Iglauer; Ronald Simon; Carsten Bokemeyer; Peter Bannas; Niklas Beumer; Charles D. Imbusch; Eray Goekkurt; Sonja Loges Introduction: The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack of development in precision...

...Aditi Kharat; Madeline Brendle; Anindit Chhibber; Nathorn Chaiyakunapruk; Joseph Biskupiak Objectives: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine monotherapy for pancreatic cancer (PC). It is still unclear...

...Savita Bisht; Peter Brossart; Georg Feldmann Summary Pancreatic cancer remains the fourth most common cause of cancer-related mortality and is a major health threat. The majority of cases are diagnosed at advanced disease stages, limiting the chances of long-term survival. Several new therapeutic...

...Savita Bisht; Georg Feldmann Summary Pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer) carries one of the poorest overall prognoses of all human malignancies known to date. Despite the introduction of novel therapeutic regimens, the outcome has not markedly improved over the past decades...

...Phyllis F. Cheung; Manfred Lutz; Jens T. Siveke Summary Pancreatic cancer is among the most aggressive malignancies with no effective therapeutic options thus far. Immunotherapy has recently emerged as a promising alternative for the treatment of various solid tumors. In particular, promising...

..., instructions or products referred to in the content or advertisements. 2017 Colorectal cancer Esophageal cancer Gastric cancer Hepatocellular carcinoma Pancreatic cancer AIDS Nowadays, HIV-infected patients may have a near-normal life expectancy if combination antiretroviral treatment...

...Arndt Vogel; Frank Kullmann; Volker Kunzmann; Salah-Eddin Al-Batran; Helmut Oettle; Ruben Plentz; Jens Siveke; Christoph Springfeld; Hanno Riess Summary In patients with advanced unresectable pancreatic cancer, the prognosis is generally poor. Within recent years, new treatment options...

... Summary of MPACT efficacy data Fig. 3 OS of patients with metastatic pancreatic cancer and first-line therapy in MPACT (intention-to-treat population). Adapted from Goldstein et al. [ 55 ]nab-P = nab-paclitaxel, Gem = gemcitabine. The combination arm was associated with grade 3...